• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dunton Alan W bought $20,250 worth of shares (6,000 units at $3.38), increasing direct ownership by 65% to 15,250 units (SEC Form 4)

    12/18/23 4:47:41 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRMD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    DUNTON ALAN W

    (Last) (First) (Middle)
    C/O CORMEDIX INC.
    300 CONNELL DRIVE

    (Street)
    BERKELEY HEIGHTS NJ 07922

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CorMedix Inc. [ CRMD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/14/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/14/2023 P 3,000 A $3.45 12,250 D
    Common Stock 12/15/2023 P 3,000 A $3.3 15,250 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Alan W. Dunton 12/18/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CRMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRMD

    DatePrice TargetRatingAnalyst
    10/20/2025$14.00Hold → Buy
    D. Boral Capital
    6/30/2025Buy → Hold
    D. Boral Capital
    6/30/2025$20.00Buy
    H.C. Wainwright
    3/7/2025$18.00Outperform
    Leerink Partners
    1/13/2025$15.00Buy
    D. Boral Capital
    8/26/2024$13.00Buy
    Rodman & Renshaw
    8/10/2023$6.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $CRMD
    SEC Filings

    View All

    SEC Form S-8 filed by CorMedix Inc.

    S-8 - CorMedix Inc. (0001410098) (Filer)

    11/13/25 4:57:39 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by CorMedix Inc.

    10-Q - CorMedix Inc. (0001410098) (Filer)

    11/12/25 8:21:01 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CorMedix Inc. (0001410098) (Filer)

    11/12/25 7:42:23 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cormedix upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Cormedix from Hold to Buy and set a new price target of $14.00

    10/20/25 9:02:46 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cormedix downgraded by D. Boral Capital

    D. Boral Capital downgraded Cormedix from Buy to Hold

    6/30/25 8:42:52 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Cormedix with a new price target

    H.C. Wainwright initiated coverage of Cormedix with a rating of Buy and set a new price target of $20.00

    6/30/25 8:34:13 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected in H1 2026 Conference call and webcast to be held Wednesday, November 12, 2025 at 4:30 pm ET SAN MATEO, Calif., Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use i

    11/12/25 4:05:00 PM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Strong Earnings and Biotech Resilience Define the Midweek Momentum

    DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kraig Labs (OTCQB:KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giants and research consortia across the globe, Kraig Biocraft Laboratories (OTCQB:KBLB) appears poised to crack biotechnology's most persistent challenge: scalable, high-performance recombinant spider silk. Kraig's imminent shipments of spider silk fiber and fabric samples to fashion and performance textile partners signal a watershed moment. Unlike fermentation-based methods that have frustrated even DuPont, BASF, and Bolt Threads, Kraig's innovation lies in reprogramming silkworms themselves to spi

    11/12/25 11:00:36 AM ET
    $CRMD
    $HUMA
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

    ‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a Range of $390 to $410 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the third quarter ended September 30, 2025 and provided an update on its business. Recent Corporate Highlights:

    11/12/25 7:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kaplan Myron bought $275,500 worth of shares (25,000 units at $11.02), increasing direct ownership by 14% to 201,034 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    10/27/25 9:30:10 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Mistry Erin bought $14,985 worth of shares (1,500 units at $9.99), increasing direct ownership by 3% to 52,011 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    12/13/24 4:15:22 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Todisco Joseph bought $50,718 worth of shares (13,561 units at $3.74), increasing direct ownership by 4% to 352,839 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    3/14/24 8:45:21 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 17, 2023 - FDA Roundup: November 17, 2023

    For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

    11/17/23 4:18:44 PM ET
    $BMY
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEFENCATH issued to CORMEDIX INC

    Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    11/15/23 9:53:06 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kaplan Myron bought $275,500 worth of shares (25,000 units at $11.02), increasing direct ownership by 14% to 201,034 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    10/27/25 9:30:10 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Duncan Gregory Scott exercised 13,333 shares at a strike of $8.32, increasing direct ownership by 53% to 38,333 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    9/18/25 9:45:02 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dunton Alan W exercised 10,000 shares at a strike of $3.55 and sold $131,300 worth of shares (10,000 units at $13.13) (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    9/16/25 9:45:02 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CorMedix Inc.

    SC 13G/A - CorMedix Inc. (0001410098) (Subject)

    11/14/24 4:34:05 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by CorMedix Inc. (Amendment)

    SC 13G/A - CorMedix Inc. (0001410098) (Subject)

    2/14/24 10:37:21 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by CorMedix Inc.

    SC 13G - CorMedix Inc. (0001410098) (Subject)

    2/13/24 5:02:29 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Leadership Updates

    Live Leadership Updates

    View All

    Talphera Announces the Appointment of Joe Todisco to Board of Directors

    SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (NASDAQ:CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of the company's private placement financing. In connection with the closing of this transaction, CorMedix has the right to nominate a representative to the Talphera Board of Directors. The Company also provided CorMedix with a 60-day exclusive negotiation period follo

    10/21/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. Announces Appointment of Chief Legal Officer

    BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023. The Company also announced that, upon mutual agreement with the Company, Dr. Phoebe Mounts will no longer serve as the Company's General Counsel, effective December 12, 2023, and will be separating from CorMedix effective December 31, 2023, to pursue other opportunities. Ms. Zelnick Kaufman has

    12/15/23 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. Announces Partnership With The Leapfrog Group

    – CorMedix to advocate for patient safety and infection prevention as part of Leapfrog's Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other purchasers focused on health care safety, whereby CorMedix Inc. will become a member of the Leapfrog Partners Advisory Committee. The Partners Advisory Committee is a platform for the crea

    12/4/23 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Financials

    Live finance-specific insights

    View All

    Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected in H1 2026 Conference call and webcast to be held Wednesday, November 12, 2025 at 4:30 pm ET SAN MATEO, Calif., Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use i

    11/12/25 4:05:00 PM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

    ‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a Range of $390 to $410 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the third quarter ended September 30, 2025 and provided an update on its business. Recent Corporate Highlights:

    11/12/25 7:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

    BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2025, before the market opens on Wednesday, November 12, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Wednesday, November 12th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Webcast:Webcast Link About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the

    10/31/25 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care